Search in:

Advanced search

Journal of Medical Economics Volume 22, 2019 - Issue 8

Submit an article Journal homepage

Free access

1,225

Views

CrossRef citations to date

Altmetric

Oncology

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

May Hagiwaraa Policy Analysis Inc. (PAI), Brookline, MA, USA; Correspondence[email protected]

Sumeet Panjabib Amgen Inc, South San Francisco, CA, USA

Arati Sharmaa Policy Analysis Inc. (PAI), Brookline, MA, USA;

Thomas E. Deleaa Policy Analysis Inc. (PAI), Brookline, MA, USA;

Pages 818-829 | Received 16 Jan 2019, Accepted 30 Apr 2019, Published online: 17 May 2019

Cite this article
https://doi.org/10.1080/13696998.2019.1614932
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions
View PDF PDF View EPUB EPUB

References

American Cancer Society. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2017. Accessed 2017 July. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf.
Google Scholar
National Comprehensive Cancer Network. The NCCN Guidelines® Version 3. Multiple Myeloma. 2017 [cited 2017 Apr 10]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf.
Google Scholar
Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–2825.
PubMed Web of Science ®Google Scholar
Celgene Corporation. Highlights of Prescribing Information for Pomalyst. 2016 [cited 2017 Jul 7]. Available from: https://media.celgene.com/content/uploads/pomalyst-pi.pdf.
Google Scholar
Chen CC, Parikh K, Abouzaid S, et al. Real-World treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. JMCP. 2017;23:236–246.
PubMed Web of Science ®Google Scholar
Amgen. Highlights of Prescribing Information for Kyprolis. [cited 2017 Jul 7]; 2012. Available from: http://pi.amgen.com/∼/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.ashx.
Google Scholar
Celgene Corporation. Highlights of Prescribing Information for Revlimid. 2015 [cited 2017 Jul 7]. Available from: https://media.celgene.com/content/uploads/revlimid-pi.pdf.
Google Scholar
Celgene Corporation. Highlights of Prescribing Information for Thalomid. [cited 2017 Jul 7]; 2017. Available from: https://media.celgene.com/content/uploads/thalomid-pi.pdf.
Google Scholar
Millennium Pharmaceuticals. Highlights of Prescribing Information for Velcade. [cited 2017, July 7]; 2017. Available from: http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf.
Google Scholar
Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Statist Med. 2009;28:3083–3107.
PubMed Web of Science ®Google Scholar
Kish L. Survey sampling. New York (NY): Wiley; 1965.
Google Scholar
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–3679.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date